Clinical Trial Update: Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial [Phase 1, Phase 2]

View source ↗

Summary

The AMBUSH trial is a Phase 1/2 study evaluating Bortezomib and Pembrolizumab with or without Pelareorep for relapsed or refractory multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• Pelareorep (pelareorep)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: University of Southern California | Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING